Table 3_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Table 5_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Table 6_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Image 1_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.tif by Zhenzhen Gu (21488168)

Table 2_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Table 1_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Table 4_Integrated analysis of miRNAs-mRNAs in skeletal muscle development revealed that novel-miR-766 affects myoblast differentiation and myofiber-type formation in sheep.xlsx by Zhenzhen Gu (21488168)

Image 1_Boys born with hypospadias and fetal growth restriction exhibit shorter anogenital distances: a retrospective cross-sectional study.tif by Wenfeng Pan (8726820)

“…Prematurity showed no significant association with AGDs.</p>Conclusion<p>Boys with hypospadias and FGR exhibit significantly shorter AGDs, with more severe hypospadias and SGA showing the strongest associations. …”

Supplementary file 1_Potential interactions between traditional Chinese medicine and osimertinib: a Case Report.docx by Min Zhang (111999)

“…<p>Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. …”

Pneumococcal (black bars) and influenza (white bars) vaccine coverage in patients living with comorbidities (A), and immunosuppressive conditions (B) according to age of 65 years,... by Benjamin Wyplosz (22032756)

Monthly and annual rate of cattle rabies occurrence in Latin America between 1970 and 2023. by Diego Soler-Tovar (20553029)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

“…Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. …”

Data Sheet 1_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx by Tien Le (634791)

“…</p>Results<p>Homozygous, crim1^−/− larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”

Table 1_Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.d... by Takeshi Osonoi (1951555)

“…As erythrocyte lifespan may affect HbA1c accuracy, this clinical trial aimed to evaluate the potential discordance between HbA1c and other glycemic markers following imeglimin therapy and to explore whether imeglimin affects erythrocytes.…”

Dataset in. CSV. by Kare Chawicha Debessa (20660605)

“…Lower dropout likelihood was significantly associated with increased age (AOR = 0.93; 95% CI: 0.89–0.97; p < 0.001) and larger family size (AOR = 0.28; 95% CI: 0.17–0.50; p < 0.001).…”

Data Sheet 1_Remarkable tumor response to Iruplinalkib in a 14-year-old girl with ALK-positive advanced metastatic non–small-cell lung cancer: a case report.pdf by Jiahao Wang (4710915)

“…<p>Targeted therapies for anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. …”

Table 1_Transcriptional patterns of brain structural abnormalities in CSVD-related cognitive impairment.docx by Haixia Mao (3775582)

“…Furthermore, a total of 1,580 genes were revealed to be significantly associated with regional change in GMV. …”

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …”